Q2 2023 · 13F-HR
Commodore Capital LPholdings as filed
Filed 2023-08-14 · accession 0001831942-23-000009
$889.8M
Reported value
26
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N5749R100 | 2GH | MERUS N V | $105.3M | 11.8% | 4,000,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $87.5M | 9.83% | 5,450,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $78.2M | 8.79% | 1,675,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $71.0M | 7.98% | 1,845,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $65.9M | 7.41% | 5,566,026 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $52.3M | 5.88% | 2,200,000 | Common | SOLE |
| 02290A102 | — | AMBRX BIOPHARMA INC | $52.3M | 5.87% | 3,175,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $50.7M | 5.70% | 1,015,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $48.5M | 5.45% | 1,150,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $47.9M | 5.39% | 2,348,272 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $30.6M | 3.44% | 2,368,186 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $22.2M | 2.49% | 2,025,000 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS IN | $21.8M | 2.44% | 610,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $21.4M | 2.41% | 631,665 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $20.9M | 2.35% | 997,596 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $18.2M | 2.05% | 775,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $17.1M | 1.92% | 900,000 | Common | SOLE |
| 00773U108 | ADVMCHF | ADVERUM BIOTECHNOLOGIES INC | $15.9M | 1.79% | 10,000,000 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $15.9M | 1.78% | 1,444,141 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $14.8M | 1.66% | 1,400,000 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $13.6M | 1.53% | 1,325,000 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $8.8M | 0.99% | 739,661 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $4.8M | 0.54% | 993,294 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $2.8M | 0.32% | 312,553 | Common | SOLE |
| 00773J103 | — | AEGLEA BIOTHERAPEUTICS INC | $1.3M | 0.15% | 2,908,100 | Common | SOLE |
| 23306J101 | — | DBV TECHNOLOGIES S A | $176,105 | 0.02% | 92,687 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.